Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
238
-
Total 13F shares, excl. options
-
50.1M
-
Shares change
-
-1.07M
-
Total reported value, excl. options
-
$2.65B
-
Value change
-
-$89M
-
Put/Call ratio
-
0.24
-
Number of buys
-
124
-
Number of sells
-
-116
-
Price
-
$53.04
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2021
298 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2021.
HAEMONETICS CORP - Common Stock (HAE) has 238 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.1M shares
.
Largest 10 shareholders include BlackRock Inc. (6.69M shares), WELLINGTON MANAGEMENT GROUP LLP (5.07M shares), VANGUARD GROUP INC (4.88M shares), Neuberger Berman Group LLC (3.88M shares), Capital Research Global Investors (2.05M shares), STATE STREET CORP (1.69M shares), FRANKLIN RESOURCES INC (1.47M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (1.29M shares), LGT CAPITAL PARTNERS LTD. (1.22M shares), and Fisher Asset Management, LLC (1.19M shares).
This table shows the top 238 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.